Avinger - AVGR Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVGR shares.
View AVGR analyst ratings or view top-rated stocks.

1 brokerages have issued 1 year price targets for Avinger's shares. Their AVGR share price forecasts range from $9.00 to $9.00. On average, they predict the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 603.1% from the stock's current price.
View analysts price targets for AVGR or view top-rated stocks among Wall Street analysts.

Avinger's stock was trading at $1.0850 at the start of the year. Since then, AVGR shares have increased by 18.0% and is now trading at $1.28.
View the best growth stocks for 2023 here.

Avinger saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 62,600 shares, a drop of 34.0% from the December 31st total of 94,800 shares. Based on an average trading volume of 52,300 shares, the short-interest ratio is currently 1.2 days. Currently, 0.9% of the shares of the company are sold short.
View Avinger's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our AVGR earnings forecast.

Avinger, Inc. (NASDAQ:AVGR) announced its quarterly earnings data on Wednesday, November, 9th. The medical device company reported ($0.77) EPS for the quarter. The medical device company earned $2.25 million during the quarter. Avinger had a negative net margin of 212.53% and a negative trailing twelve-month return on equity of 244.04%.

Avinger shares reverse split on Tuesday, March 15th 2022. The 1-20 reverse split was announced on Tuesday, March 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avinger investors own include Bionano Genomics (BNGO), Novan (NOVN), Titan Pharmaceuticals (TTNP), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Organigram (OGI), Onconova Therapeutics (ONTX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS) and Actinium Pharmaceuticals (ATNM).

(AVGR) raised $60 million in an initial public offering on Friday, January 30th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company acted as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers.

Avinger trades on the NASDAQ under the ticker symbol "AVGR."

Shares of AVGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVGR stock can currently be purchased for approximately $1.28.

Avinger (NASDAQ:AVGR) has a market capitalization of $9.52 million and generates $8.68 million in revenue each year. The medical device company earns $-17,410,000.00 in net income (profit) each year or ($5.30) on an earnings per share basis.

Avinger's mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.avinger.com. The medical device company can be reached via phone at (650) 241-7900, via email at info@dawson3d.com, or via fax at 800-229-2696.